Ascendis Pharma A/S and Pharming Group N.V.: SG&A Spending Patterns Compared

SG&A Spending Patterns: Ascendis Pharma A/S vs. Pharming Group N.V.

In the competitive landscape of the pharmaceutical industry, understanding spending patterns is crucial. Over the past decade, Ascendis Pharma A/S and Pharming Group N.V. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. Ascendis Pharma A/S has seen a dramatic increase, with expenses growing by over 4,100% from 2014 to 2023. In contrast, Pharming Group N.V. experienced a more modest rise of approximately 2,100% during the same period.

Key Insights

• 2014-2016: Both companies maintained relatively low SG&A expenses, with Ascendis Pharma A/S starting at $6.3 million and Pharming Group N.V. at $4 million.
• 2017-2020: Ascendis Pharma A/S began to outpace Pharming Group N.V., doubling its expenses by 2020.
• 2021-2023: Ascendis Pharma A/S's expenses surged, reaching $264 million, while Pharming Group N.V. peaked at $132 million in 2022.

These trends highlight Ascendis Pharma A/S's aggressive growth strategy, while Pharming Group N.V. maintains a steadier approach.